# A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients

> **NCT01634243** · PHASE2 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 64 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** SPM 962

## Key facts

- **NCT ID:** NCT01634243
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-01
- **Primary completion:** 2006-05
- **Final completion:** 2006-05
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2014-03-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01634243

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01634243, "A Dose-ranging Study for SPM 962 in Parkinson's Disease Patients". Retrieved via AI Analytics 2026-06-21 from https://api.ai-analytics.org/clinical/NCT01634243. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*